Abbvie Inc
NYSE:ABBV
Intrinsic Value
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one
ABBV
stock under the Base Case scenario is
119.04
USD.
Compared to the current market price of 149.06 USD,
Abbvie Inc
is
Overvalued by 20%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Abbvie Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Abbvie Inc
| Current Assets | 28.9B |
| Cash & Short-Term Investments | 8.8B |
| Receivables | 11.5B |
| Other Current Assets | 8.6B |
| Non-Current Assets | 107B |
| Long-Term Investments | 288m |
| PP&E | 4.9B |
| Intangibles | 95.1B |
| Other Non-Current Assets | 6.2B |
| Current Liabilities | 32.2B |
| Accounts Payable | 27B |
| Other Current Liabilities | 5.2B |
| Non-Current Liabilities | 90.3B |
| Long-Term Debt | 55.8B |
| Other Non-Current Liabilities | 34.5B |
ABBV Profitability Score
Profitability Due Diligence
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
ABBV Solvency Score
Solvency Due Diligence
Abbvie Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Abbvie Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for
ABBV
is 172.52 USD
with a low forecast of 136.35 USD and a high forecast of 215.25 USD.
Ownership
ABBV Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ABBV Price
Abbvie Inc
| Average Annual Return | 14.95% |
| Standard Deviation of Annual Returns | 17.83% |
| Max Drawdown | -31% |
| Market Capitalization | 263B USD |
| Shares Outstanding | 1 776 000 000 |
| Percentage of Shares Shorted | 0.71% |
ABBV News
Last Video News
Abbvie Inc
Last Important Events
Abbvie Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Abbvie Inc
Company Profile
Abbvie Inc
Country
Industry
Market Cap
Dividend Yield
Description
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.
Contact
IPO
Employees
Officers
The intrinsic value of one
ABBV
stock under the Base Case scenario is
119.04
USD.
Compared to the current market price of 149.06 USD,
Abbvie Inc
is
Overvalued by 20%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
